Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3551
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Linh, N. T. D., Hồng, V. D., Tân, N. D., Anh, T. D., Anh, L. T. H., Thảo, L. P., Hà, T. T. T., Nhật, N. Q., Thảo, T. P., Trang, T. T. T., & Phương, Đồng T. X. (2025). 23. Evaluation of knowledge, attitudes, and practices of outpatients with chronic myeloid leukemia undergoing imatinib treatment at the National Institute of Hematology and Blood transfusion. Journal of Medical Research, 192(7), 208-219. https://doi.org/10.52852/tcncyh.v192i7.3551

23. Evaluation of knowledge, attitudes, and practices of outpatients with chronic myeloid leukemia undergoing imatinib treatment at the National Institute of Hematology and Blood transfusion

Nguyen Thi Dieu Linh, Vu Duy Hong, Nguyen Duy Tan, Tran Duy Anh, Le Thi Hong Anh, Le Phuong Thao, Tran Thi Thu Ha, Nguyen Quoc Nhat, Tran Phuong Thao, Tran Thi Thu Trang, Dong Thi Xuan Phương

Main Article Content

Abstract

Imatinib is regarded as the first-line therapy for Chronic Myeloid Leukemia (CML); however, its clinical efficacy is substantially contingent upon patient adherence. Knowledge, attitude, and practice (KAP) have been identified as pivotal determinants of therapeutic outcomes. In a cross-sectional descriptive study from October 2024 to the end of February 2025 at the National Institute of Hematology and Blood Transfusion, direct interviews were conducted to 200 CML patients ((median age, 45 (18 - 97); 52.7% male)) to assess KAP parameters. Although attitudes and adherence behaviors were generally favorable, disease-specific knowledge remained suboptimal (median KAP scores: knowledge 10 (2 - 18); attitude 35 (24 - 45); practice 29 (17 - 35). The demonstrated correlation between knowledge and attitude-practice underscores the imperative to embed comprehensive interventions-encompassing patient education, awareness enhancement, and psychosocial support-into clinical care pathways in order to optimize Imatinib adherence among CML patients.

Article Details

Keywords

Chronic myeloid leukemia, adherence, imatinib, knowledge, attitude, practice

References

1. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leukemia & lymphoma. Jul 2013; 54(7): 1411-7. doi:10.3109/10428194.2012.745525.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a cancer journal for clinicians. Jan 2022; 72(1): 7-33. doi:10.3322/caac.21708.
3. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. The New England journal of medicine. Mar 9 2017; 376(10): 917-927. doi:10.1056/NEJMoa1609324.
4. Cheng F, Cui Z, Li Q, Wang L, Li W. Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia. Int Immunopharmacol. Nov 2023; 124(Pt A): 110847. doi:10.1016/j.intimp.2023.110847.
5. Santoleri F, Lasala R, Ranucci E, et al. Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Acta Haematol. 2016; 136(1): 45-51. doi:10.1159/000444626.
6. Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009; 113(22): 5401-5411. doi:10.1182/blood-2008-12-196543.
7. Song L, Guo J, Zhou D, et al. Assessment of knowledge, attitudes, and practices of CML patients and their families toward TKI therapy in China. Medicine. Dec 15 2023; 102(50): e36498. doi:10.1097/md.0000000000036498.
8. Stone JK, Shafer LA, Graff LA, et al. Utility of the MARS-5 in Assessing Medication Adherence in IBD. Inflammatory bowel diseases. Feb 16 2021; 27(3): 317-324. doi:10.1093/ibd/izaa056.
9. Awwad O, Akour A, Al-Muhaissen S, Morisky D. The influence of patients’ knowledge on adherence to their chronic medications: a cross-sectional study in Jordan. International journal of clinical pharmacy. Jun 2015; 37(3): 504-10. doi:10.1007/s11096-015-0086-3.
10. Pavlovsky C, Abello Polo V, Pagnano K, et al. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Advances. 2021; 5(23): 4855-4863. doi:10.1182/bloodadvances.2020003235.
11. Efficace F, Breccia M, Cottone F, et al. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. Dec 2016; 24(12): 4887-4894. doi:10.1007/s00520-016-3344-6.
12. Hao T, Li-Talley M, Buck A, Chen W. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Scientific reports. Aug 19 2019; 9(1): 12070. doi:10.1038/s41598-019-48445-1.
13. Blanke CD, Huse DM. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. Journal of medical economics. 2010; 13(4): 681-90. doi:10.3111/13696998.2010.534670.
14. Krist AH, Tong ST, Aycock RA, Longo DR. Engaging Patients in Decision-Making and Behavior Change to Promote Prevention. Studies in health technology and informatics. 2017; 240: 284-302.
15. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Therapeutics and clinical risk management. Sep 2005; 1(3): 189-99.